-
71.发明授权公开(公告)号：US07563930B2
公开(公告)日：2009-07-21
申请号：US11605149
申请日：2006-11-22
IPC分类号： C07C211/00
CPC分类号： C07C211/30 , A61K31/137
摘要： Provided are crystalline forms of Cinacalet HCl and processes for their preparation.
摘要翻译： 提供的是Cinacalet HCl的结晶形式及其制备方法。
-
公开(公告)号：US20090030057A1
公开(公告)日：2009-01-29
申请号：US12151818
申请日：2008-05-08
申请人： Shlomit Wizel , Gershon Kolatkar , Erela Zisman
发明人： Shlomit Wizel , Gershon Kolatkar , Erela Zisman
IPC分类号： A61K31/4184 , C07D403/10
CPC分类号： A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K31/4184
摘要： The present invention provides a pharmaceutical composition of telmisartan comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent wherein the composition comprises less than 25% of water soluble diluents. The telmisartan compound is preferably present from about 12.5% to about 15.5%. At least one water insoluble diluent is preferred for use in the pharmaceutical composition in an amount from about 40% to about 70% of the total weight of the pharmaceutical composition. A preferred water insoluble diluent is microcrystalline cellulose. Also described are a pharmaceutical composition comprising telmisartan having a powder X-ray diffraction pattern, methods of preparing such pharmaceutical composition, and a crystalline form of Telmisartan.
摘要翻译： 本发明提供了替米沙坦的药物组合物，其包含a）替米沙坦化合物，b）表面活性剂，c）碱性试剂，和d）至少一种稀释剂，其中所述组合物包含少于25％的水溶性稀释剂。 替米沙坦化合物优选以约12.5％至约15.5％存在。 至少一种不溶于水的稀释剂优选用于药物组合物中，其量为药物组合物总重量的约40％至约70％。 优选的水不溶性稀释剂是微晶纤维素。 还描述了包含具有粉末X射线衍射图的替米沙坦，制备该药物组合物的方法和替米沙坦的结晶形式的药物组合物。
-
公开(公告)号：US20080319075A1
公开(公告)日：2008-12-25
申请号：US12150062
申请日：2008-04-23
申请人： Ronit Yahalomi , Evgeny Shapiro , Ben-Zion Dolitzky , Igal Gozlan , Boaz Gome , Shlomit Wizel
发明人： Ronit Yahalomi , Evgeny Shapiro , Ben-Zion Dolitzky , Igal Gozlan , Boaz Gome , Shlomit Wizel
IPC分类号： A61K31/195 , C07C229/36
CPC分类号： C07C233/63 , A61K31/16 , A61K31/198 , C07B2200/13 , C07C51/60 , C07C231/02 , C07C231/24 , C07C2601/14 , C07C61/08
摘要： Provides are crystalline forms of nateglinide, labeled Forms A, C, D, F, G, I, J, K, L, M, N, O, P, Q, T, U, V, Y, α, β, γ, δ, ε, σ, θ and Ω, processes for their preparation and processes for preparation of other crystalline forms of nateglinide. Also provided are their pharmaceutical formulations and methods of administration.
-
公开(公告)号：US20080269488A1
公开(公告)日：2008-10-30
申请号：US12217251
申请日：2008-07-01
IPC分类号： C07D401/10
CPC分类号： C07D215/56 , C07D401/04
摘要： Provided are two novel crystalline forms of gatifloxacin, denominated form O and form V, and methods for their preparation.
摘要翻译： 提供加替沙星的两种新型结晶形式，称为O型和V型，其制备方法。
-
公开(公告)号：US07396839B2
公开(公告)日：2008-07-08
申请号：US10635337
申请日：2003-08-06
IPC分类号： C07D401/04
CPC分类号： C07D215/56 , C07D401/04
摘要： Provided are novel crystalline forms of gatifloxacin, denominated forms L, M, P, Q, S, and T1, and methods for making them. Also provided are methods of transforming the novel crystalline forms of gatifloxacin of the present invention to other crystalline forms of gatifloxacin.
摘要翻译： 提供加替沙星的新型结晶形式，称为L，M，P，Q，S和T1，以及制备它们的方法。 还提供了将本发明的加替沙星的新结晶形式转化为加替沙星的其它结晶形式的方法。
-
76.发明授权Amorphous and crystalline forms of losartan potassium and process for their preparation 失效氯沙坦钾的无定形和结晶形式及其制备方法公开(公告)号：US07332612B2
公开(公告)日：2008-02-19
申请号：US10293820
申请日：2002-11-13
IPC分类号： C07D403/10
CPC分类号： C07D403/10
摘要： This invention relates to novel amorphous losartan potassium, novel losartan potassium in a crystalline form that is a hydrate, novel crystalline losartan potassium Form IV and solvates thereof, novel crystalline losartan potassium Form V and solvates thereof, to processes for their preparation, to compositions containing them and to their use in medicine. This invention further relates to a novel process for preparing crystalline losartan potassium Form I and Form II.
摘要翻译： 本发明涉及新型无定形洛沙坦钾，结晶形式的新型氯沙坦钾，其为水合物，新型结晶氯沙坦钾形式IV及其溶剂合物，新型结晶氯沙坦钾V型及其溶剂化物，其制备方法，含有 他们和他们在医学中的使用。 本发明还涉及一种制备结晶氯沙坦钾I型和II型的新方法。
-
公开(公告)号：US07301024B2
公开(公告)日：2007-11-27
申请号：US10735029
申请日：2003-12-12
IPC分类号： C07D401/04
CPC分类号： C07D215/56 , C07D215/233
摘要： Provided are novel crystalline forms of gatifloxacin, some of which are DMSO solvates, and methods for making them.
摘要翻译： 提供加替沙星的新型结晶形式，其中一些是DMSO溶剂合物，以及制备它们的方法。
-
公开(公告)号：US20070043094A1
公开(公告)日：2007-02-22
申请号：US11588497
申请日：2006-10-27
IPC分类号： A61K31/426 , C07D277/02
CPC分类号： C07D417/12
摘要： Provided is a novel crystal form of pioglitazone hydrochloride and a method for making it. Also provided is a method for making a known crystal form of pioglitazone hydrochloride.
摘要翻译： 提供了盐酸吡格列酮的新型晶体形式及其制备方法。 还提供了制备盐酸吡格列酮的已知晶体形式的方法。
-
公开(公告)号：US20060293377A1
公开(公告)日：2006-12-28
申请号：US11267520
申请日：2005-11-03
申请人： Shlomit Wizel , Nurit Perlman , Sharon Avhar-Maydan , Eyal Gilboa
发明人： Shlomit Wizel , Nurit Perlman , Sharon Avhar-Maydan , Eyal Gilboa
IPC分类号： A61K31/4184 , C07D403/02
CPC分类号： C07D235/20
摘要： Provided is the amorphous form of telmisartan sodium and the preparation thereof. Also provided are the telmisartan sodium polymorph crystal Forms 0 to XIII and XV to XX and preparations thereof. Also provided are pharmaceutical composition of amorphous and polymorphic forms of telmisartan sodium or mixtures thereof, and methods of treatment of a mammal in need thereof.
摘要翻译： 提供替米沙坦钠的无定形形式及其制备方法。 还提供了替米沙坦钠多晶型晶型0至XIII和XV至XX及其制剂。 还提供了替米沙坦钠或其混合物的无定形和多晶型形式的药物组合物，以及治疗有需要的哺乳动物的方法。
-
80.发明申请公开(公告)号：US20060258677A1
公开(公告)日：2006-11-16
申请号：US11488371
申请日：2006-07-17
IPC分类号： A61K31/496 , C07D403/02
CPC分类号： C07D215/233
摘要： Provided are novel crystalline forms of gatifloxacin, some of which are DMSO solvates, and methods for making them.
摘要翻译： 提供加替沙星的新型结晶形式，其中一些是DMSO溶剂合物，以及制备它们的方法。
-
-
-
-
-
-
-
-
-
搜索结果
91 条记录 (耗时 0.028 秒)
